ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

EB-DUO-CAR-NK-CEA/GCC

Also written as “EB-DUO-CAR-NK-CEA/GCC (IV)”.

Its studies are mostly in Colorectal Neoplasms · Colonic Neoplasms, led by Beijing Biotech.

Furthest: phase 2, since Feb 14, 20262 company-led studies, 2 open or runningNext primary completion: Mar 14, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Beijing Biotech22 open or runningphase 2since Feb 14, 2026Feb 14, 2026Mar 14, 2027phase 2 · NCT07589517

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Feb 14, 2026First study: phase 2 study in Colonic NeoplasmsFirst studyNCT07462650 · 48 planned · China
  2. May 10, 2026Phase 2 study in Colorectal NeoplasmsNCT07589517 · 48 planned · China

Ahead

  1. Mar 14, 2027Primary completion: phase 2 study in Colorectal NeoplasmsNCT07589517
  2. Dec 21, 2027Primary completion: phase 2 study in Colonic NeoplasmsNCT07462650

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07589517Colorectal Neoplasms · China2RecruitingMar 14, 202748
NCT07462650Colonic Neoplasms · China2RecruitingDec 21, 202748

How it is read

Names in the registry

  • “EB-DUO-CAR-NK-CEA/GCC”, 1 entry
  • “EB-DUO-CAR-NK-CEA/GCC (IV)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.